AUSTIN, TX and TORONTO, March 13, 2013 /CNW/ - Affinium Pharmaceuticals
announced today the expansion of its leadership team with the
appointment of two senior biotech and pharmaceutical executives to its
leadership team: Ed Mascioli, M.D. is appointed Chief Executive
Officer (CEO), and Mr. Robert (Bob) Radie is appointed to the Board of
Dr. Mascioli is an experienced pharmaceutical and venture executive, and
held prior positions as a senior executive at Pfizer, Inc., Dapis
Capital, Peptimmune, Inc. and MPM Capital. Mr. Radie is currently
President and Chief Executive Officer of Egalet, a specialty
pharmaceutical company developing tamper-resistant pain medicines.
"We are very pleased to welcome both of these talented executives to key
leadership roles at Affinium," stated Dr. Stuart Collinson, Chairman of
the Board at Affinium Pharmaceuticals. "As we progress past the
clinical proof-of-concept stage for our novel antibiotic, Dr. Mascioli
and Mr. Radie bring key business development expertise to our current
discussions with potential partners."
About Staphylococcal Infections
Staphylococcus is the mostly commonly identified bacterial pathogen in humans and is a
potential pathogen in almost every type of bacterial infection.
Methicillin-resistant strains of S. aureus (MRSA) account for about half of all S. aureus strains in the US and causes significant morbidity and mortality
worldwide. According to the Infectious Disease Society of America
(IDSA), MRSA kills more Americans every year then emphysema, HIV/AIDS,
Parkinson's Disease and homicide combined.1
AFN-1252 is the lead clinical-stage agent in a new class of antibiotics
based on FabI inhibition.
Due to its unique, staphylococcal-specific spectrum, AFN-1252 is expected to have no off-target side effects, such as
antibiotic-induced diarrhea or C. difficile overgrowth, and no resistance pressure on other bacteria; consequently,
the development of multiply-drug-resistant organisms like
vancomycin-resistant enterococci (VRE) is unlikely. AFN-1252 is 10-20
times more potent than linezolid in animal models of infection, and is
exquisitely potent against all strains of Staphylococcus, including all known resistant strains such as MRSA and
vancomycin-intermediate S. aureus (VISA). AFN-1252 has the potential to be used either as monotherapy
for confirmed staphylococcal infections or in combination when MRSA is
suspected in a variety of infections. Both oral and IV formulations
are in development.
About Affinium Pharmaceuticals
Affinium Pharmaceuticals is a specialty pharmaceutical company focused
on the development of novel anti-infective medicines based on bacterial
fatty acid inhibition. This antibacterial program constitutes a new
antibiotic platform with the potential for multiple patented products
targeting the FabI target in several different bacterial species.
For more information, please see our website at: www.afnm.com
SOURCE: Affinium Pharmaceuticals
For further information:
Ed Mascioli, M.D.
Chief Executive Officer